Quest Diagnostics traded at $234.40 this Friday August 14th, decreasing $1.64 or 0.69 percent since the previous trading session. Looking back, over the last four weeks, Quest Diagnostics lost 16.17 percent. Over the last 12 months, its price rose by 30.39 percent. Looking ahead, we forecast Quest Diagnostics to be priced at 229.36 by the end of this quarter and at 214.88 in one year, according to Trading Economics global macro models projections and analysts expectations.
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.